Home›Trial›NCT07153146
NCT07153146Phase 1RECRUITING

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

Study Summary

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.

Conditions
Healthy Volunteer
Interventions / Drugs
PN-881 Oral SolutionPN-881 Oral TabletPlacebo
View on ClinicalTrials.gov ↗
Sponsor
PTGX
Protagonist Therapeutics
Peptide Therapeutics
D44/100
Study Details
Enrollment142 participants
Primary Completion—
Lead SponsorProtagonist Therapeutics, Inc.
Data Retrieved2026-04-11 04:25:05.763726+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 142 participants
Sponsor Catalyst Profile

Protagonist Therapeutics (PTGX) is the sponsoring company for this trial. BiotechSign currently grades this company D (44/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PTGX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.